These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22041919)

  • 1. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
    Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
    J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characteristics and biological behaviours of the oncocytic and pancreatobiliary subtypes of intraductal papillary mucinous neoplasms.
    Xiao HD; Yamaguchi H; Dias-Santagata D; Kuboki Y; Akhavanfard S; Hatori T; Yamamoto M; Shiratori K; Kobayashi M; Shimizu M; Fernandez-Del Castillo C; Mino-Kenudson M; Furukawa T
    J Pathol; 2011 Aug; 224(4):508-16. PubMed ID: 21547907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas.
    Furukawa T; Fujisaki R; Yoshida Y; Kanai N; Sunamura M; Abe T; Takeda K; Matsuno S; Horii A
    Mod Pathol; 2005 Aug; 18(8):1034-42. PubMed ID: 15832194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas.
    Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH
    Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
    Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
    Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shiratori K; Kawamura S; Kobayashi M; Shimizu M; Ban S; Koyama I; Higashi M; Shin N; Ishida K; Morikawa T; Motoi F; Unno M; Kanno A; Satoh K; Shimosegawa T; Orikasa H; Watanabe T; Nishimura K; Harada Y; Furukawa T
    Am J Surg Pathol; 2011 Dec; 35(12):1812-7. PubMed ID: 21945955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
    Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
    Nissim S; Idos GE; Wu B
    Pancreas; 2012 Nov; 41(8):1195-205. PubMed ID: 22750975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS.
    Chang XY; Wu Y; Li Y; Wang J; Chen J
    Mol Med Rep; 2018 Jun; 17(6):8061-8068. PubMed ID: 29658583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of clonality of multisegmental main duct intraductal papillary mucinous neoplasms of the pancreas based on GNAS mutation analysis.
    Tamura K; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Ideno N; Aso T; Miyazaki T; Ohuchida K; Takahata S; Ito T; Ushijima Y; Oda Y; Mizumoto K; Tanaka M
    Surgery; 2015 Feb; 157(2):277-84. PubMed ID: 25530484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
    Schönleben F; Qiu W; Remotti HE; Hohenberger W; Su GH
    Langenbecks Arch Surg; 2008 May; 393(3):289-96. PubMed ID: 18343945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.
    Matthaei H; Norris AL; Tsiatis AC; Olino K; Hong SM; dal Molin M; Goggins MG; Canto M; Horton KM; Jackson KD; Capelli P; Zamboni G; Bortesi L; Furukawa T; Egawa S; Ishida M; Ottomo S; Unno M; Motoi F; Wolfgang CL; Edil BH; Cameron JL; Eshleman JR; Schulick RD; Maitra A; Hruban RH
    Ann Surg; 2012 Feb; 255(2):326-33. PubMed ID: 22167000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features.
    Shimizu T; Akita M; Sofue K; Toyama H; Itoh T; Fukumoto T; Zen Y
    Hum Pathol; 2019 Sep; 91():26-35. PubMed ID: 31175918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas.
    Schönleben F; Qiu W; Bruckman KC; Ciau NT; Li X; Lauerman MH; Frucht H; Chabot JA; Allendorf JD; Remotti HE; Su GH
    Cancer Lett; 2007 May; 249(2):242-8. PubMed ID: 17097223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
    Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
    J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.